Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stockwatch: The difficult art of painting oneself out of a corner

This article was originally published in Scrip

Executive Summary

As ever, those efficient accountants and auditors at Cubist Pharmaceuticals made sure that that the company again kicked off as early as possible the first half of 2011 earnings season on Thursday. While the announced a five percent increase in quarterly sales over Q2 2010 from its antibiotic Cubicin (daptomycin) for severe hospital infections, the challenge for Cubist is to build a sustainable business on product that everybody desires but no-one wants to use. Within the last few months, Cubist had been reported to be a takeover target first for AstraZeneca and then for Shire, although no deal has materialised.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts